韩国药品专利保护期补偿制度对中国新药研发的启示  

The inspiration to new drug research and development in China from the drug patent time extended in Korea

作　　者：顾东蕾 潘晓梅 郑永男 简宇聪 兴星 GU Dong-lei;PAN Xiao-mei;ZHENG Yong-nan;JIAN Yu-cong;XING Xing(Library and Information Center of China Pharmaceutical University,Nanjing 211198,China;Daweisoft Co.,Ltd.,Baoding 071052,China;Shenzhen Main Luck Pharmaceuticals Inc,Shenzhen 518029,China)

机构地区：[1]中国药科大学图书与信息中心,南京211198 [2]保定市大为计算机软件开发有限公司,保定071052 [3]深圳万乐药业有限公司,深圳518029

出　　处：《中国新药杂志》2022年第12期1151-1156,共6页Chinese Journal of New Drugs

基　　金：国家知识产权局软科学研究项目:大数据视阈之下中国药品专利链接制度战略研究(SS18-B-25);中央高校基本科研业务费校级平台基地建设项目:生物医药知识产权信息管理及数据挖掘平台(2632017PT06)。

摘　　要：在新专利法背景下,本文对韩国在引入美国药品专利保护期限补偿制度后进行的专利法修改进行研究,对韩国食品药品安全部公布的药品专利清单中获准药品专利保护期限补偿的数据进行挖掘,对韩国获准专利保护期限补偿的药品在我国的上市状态和专利保护程度进行解析,提出我国获准药品专利保护期限补偿有必要区分同一件专利的不同权项建议,同时为我国仿创药品的品种筛选提供参考。In the context of the new patent law,this paper studied the correction of the patent law carried out by the Republic of Korea after introduction of the drug patent time extended in the United States,excavated the data of the drug patent time extended in the patent list in the Ministry of Food and Drug Safety in the Republic of Korea and analyzed the market and patent of the drugs granted time extention from the Republic of Korea in China.It was suggested that it is necessary to distinguish different extended rights of the same patent.This paper also provided reference for the selection varies between generic drugs and reference listed drugs in China.

关 键 词：药品专利保护期限补偿 专利法 韩国 

分 类 号：R951[医药卫生—药学]